AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Nis Register Study Comparing Seroquel and Seroquel Prolong
Completed
- Conditions
- Comparing Hospitalisation Time With Seroquel and Seroquel Prolong
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00965536
- Locations
- 🇫🇮
Research Site, Lappeenranta, Finland
AZD5423 Single Ascending Dose Study
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT00963183
- Locations
- 🇬🇧
Research Site, London, United Kingdom
AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00963365
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00963144
- Locations
- 🇲🇾
Research Site, Selangor, Malaysia
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1036
- Registration Number
- NCT00960661
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)
Phase 1
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Device: AZD1656
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2009-09-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00960791
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 282
- Registration Number
- NCT00960076
- Locations
- 🇵🇪
Research Site, Lima, Peru
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
Phase 1
Completed
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT00960349
- Locations
- 🇯🇵
Research Site, Chuo, Tokyo, Japan
Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00957437
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Completed
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2010-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00956280
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil